Home > Insider Trading > Filing (0001127602-12-028351)

Filing Details

Accession Number:: 0001127602-12-028351
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-10-05 19:21:03
Reporting Period:: 2012-10-04

Filing Date:: 2012-10-05
Accepted Time:: 2012-10-05 19:21:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
850693	Allergan Inc	AGN	Pharmaceutical Preparations (2834)	951622442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1051578	I E David Pyott	2525 Dupont Drive Irvine CA 92612	Chairman, President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2012-09-21	19,473	$0.00	165,000	No	5	G	Direct
Common Stock	Acquisiton	2012-09-21	19,473	$0.00	226,396	No	5	G	Indirect	By Living Trust
Common Stock	Disposition	2012-10-04	206,923	$93.74	19,473	No	4	S	Indirect	By Living Trust
Common Stock	Acquisiton	2012-10-04	119,000	$30.13	138,473	No	4	M	Indirect	By Living Trust
Common Stock	Acquisiton	2012-10-04	90,623	$41.24	229,096	No	4	M	Indirect	By Living Trust
Common Stock	Acquisiton	2012-10-04	101,421	$41.24	330,517	No	4	M	Indirect	By Living Trust
Common Stock	Disposition	2012-10-04	101,421	$93.71	229,096	No	4	S	Indirect	By Living Trust
Common Stock	Acquisiton	2012-10-05	307,956	$41.24	537,052	No	4	M	Indirect	By Living Trust
Common Stock	Disposition	2012-10-05	307,956	$93.72	229,096	No	4	S	Indirect	By Living Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	5	G	Indirect	By Living Trust
No	4	S	Indirect	By Living Trust
No	4	M	Indirect	By Living Trust
No	4	M	Indirect	By Living Trust
No	4	M	Indirect	By Living Trust
No	4	S	Indirect	By Living Trust
No	4	M	Indirect	By Living Trust
No	4	S	Indirect	By Living Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-10-04	119,000	$0.00	119,000	$30.13
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-10-04	90,623	$0.00	90,623	$41.24
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-10-04	101,421	$0.00	101,421	$41.24
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-10-05	307,956	$0.00	307,956	$41.24

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-01-30	No	4	M	Indirect
409,377	2014-01-29	No	4	M	Indirect
307,956	2014-01-29	No	4	M	Indirect
0	2014-01-29	No	4	M	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,171	Indirect	By 401(k) Trust
Common Stock	2,885	Indirect	By Esop Trust

Footnotes

Transfer of 19,473 shares held directly by the reporting person to the David & Julianna Pyott Living Trust.
David and Julianna Pyott Living Trust dated June 14, 1999, in which the reporting person has a pecuniary interest and of which the reporting person and his spouse are each trustees.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2012.
The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $93.3950 to $93.9850, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $93.5400 to $93.9900, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $$93.4800 to $94.3600, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Shares allocated to reporting person's SIP account as of reporting date.
Shares allocated to the reporting person's ESOP account as of reporting date.
The option becomes exercisable in four equal annual installments beginning January 31, 2004.
The option becomes exercisable in four equal annual installments beginning January 30, 2005.